ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. (11th September 2020)

• Record Type: Journal Article
• Authors: Zheng, X. Long; Vesely, Sara K.; Cataland, Spero R.; Coppo, Paul; Geldziler, Brian; Iorio, Alfonso; Matsumoto, Masanori; Mustafa, Reem A.; Pai, Menaka; Rock, Gail; Russell, Lene; Tarawneh, Rawan; Valdes, Julie; Peyvandi, Flora
• Is Part Of: Journal of thrombosis and haemostasis. Volume 18:Number 10(2020)
• Page Start: 2486
• Page End: 2495
• Publication Date: 2020-09-11
• Subjects: ADAMTS13 -- diagnosis -- guidelines -- thrombosis -- TTP; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15006
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly. Objective: The evidence‐based guidelines of the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients, clinicians, and other health care professionals in their decisions about the initial diagnosis and management of acute TTP. Methods: In June 2018, ISTH formed a multidisciplinary panel that included hematologists, an intensive care physician, nephrologist, clinical pathologist, biostatistician, and patient representatives, as well as a methodology team from McMaster University. The panel composition was designed to minimize the potential conflicts of interests. The panel used the Grading of Recommendations Assessment, Development, and Evaluation approach and the Population, Intervention, Comparison, Outcome framework to develop and grade their recommendations. Public comments were sought and incorporated in the final document. Results: The panel agreed on three recommendations covering the initial diagnosis with emphasis on the importance of ADAMTS13 testing (eg, activity, anti‐ADAMTS13 IgG or inhibitor) and assessment of the pretest probability of TTP by clinical assessment and/or the risk assessment models like the PLASMIC or French score. The panel noted how availability and turnaround time of ADAMTS13 test results might affect early diagnosis and management, in particular the use of caplacizumab. Conclusions: There is a lack of high‐quality evidence to support strong recommendations for the initial diagnosis and management of a suspected TTP. The panel emphasized the importance of obtaining ADAMTS13 testing in a proper clinical context. Future research should focus on how to monitor and act on ADAMTS13 levels during remission.